Managing Director, CRI Venture Fund,
Program Director, Clinical Accelerator, and
Owner, Startist Innovations
Adam Kolom developed and currently serves as managing director of the CRI Venture Fund, a philanthropist-backed venture capital fund that invests in the early stage development of promising new immunotherapies for cancer, and program director of the Clinical Accelerator, a global research collaboration of top academic investigators and for-profit biopharmaceutical companies dedicated to accelerating development of more effective combination treatments for cancer.
Prior to founding CRI's venture fund and accelerator, Adam was a member of the healthcare investment team at $17Bn growth equity fund General Atlantic in New York, a management consultant at McKinsey & Company in London and Connecticut, and an investment banker at UBS in Los Angeles. He is also the founder of Startist Innovations, a growth stage consumer product and software development company, and advisor to a number of VC-backed companies. Adam graduated with honors from the Wharton School at the University of Pennsylvania with a degree in finance and economics.
Adam has watched eight members of his immediate and extended family battle cancer, both with and without success, and is passionate about helping to better bridge the capabilities of the for-profit and nonprofit sectors to speed up development of more effective treatments.